Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Total Valuation
Fulcrum Therapeutics has a market cap or net worth of $186.77M. The enterprise value is $21.19M.
Market Cap$186.77M
Enterprise Value$21.19M
Share Statistics
Fulcrum Therapeutics has 53,979,305 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,979,305
Owned by Insiders7.54%
Owned by Institutions<0.01%
Financial Efficiency
Fulcrum Therapeutics’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -44.95%.
Return on Equity (ROE)-0.41
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-44.95%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee62.33K
Profits Per Employee-2.16M
Employee Count45
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fulcrum Therapeutics is -4.25. Fulcrum Therapeutics’s PEG ratio is 0.13.
PE Ratio-4.25
PS Ratio2.13
PB Ratio1.76
Price to Fair Value1.76
Price to FCF-4.52
Price to Operating Cash Flow-4.55
PEG Ratio0.13
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 2.81M and earned -97.33M in profits. Earnings per share was -1.59.
Revenue2.81M
Gross Profit2.81M
Operating Income-110.66M
Pretax Income-97.33M
Net Income-97.33M
EBITDA-108.49M
Earnings Per Share (EPS)-1.59
Cash Flow
In the last 12 months, operating cash flow was -2.22M and capital expenditures -278.00K, giving a free cash flow of -2.50M billion.
Operating Cash Flow-2.22M
Free Cash Flow-2.50M
Free Cash Flow per Share-0.05
Dividends & Yields
Fulcrum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change-50.94%
50-Day Moving Average3.19
200-Day Moving Average4.78
Relative Strength Index (RSI)66.23
Average Volume (3m)393.16K
Important Dates
Fulcrum Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Fulcrum Therapeutics as a current ratio of 17.71, with Debt / Equity ratio of 3.55%
Current Ratio17.71
Quick Ratio17.71
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fulcrum Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fulcrum Therapeutics EV to EBITDA ratio is -3.68, with an EV/FCF ratio of -4.36.
EV to Sales142.28
EV to EBITDA-3.68
EV to Free Cash Flow-4.36
EV to Operating Cash Flow-4.39
Balance Sheet
Fulcrum Therapeutics has $241.02M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$232.39M billion.
Cash & Marketable Securities$241.02M
Total Debt$0.00
Net Cash-$232.39M
Net Cash Per Share-$4.31
Tangible Book Value Per Share$3.84
Margins
Gross margin is 77.83%, with operating margin of -3945.24%, and net profit margin of -3470.05%.
Gross Margin77.83%
Operating Margin-3945.24%
Pretax Margin-3470.05%
Net Profit Margin-3470.05%
EBITDA Margin-3867.81%
EBIT Margin-3945.24%
Analyst Forecast
The average price target for Fulcrum Therapeutics is $5.67, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$5.67
Price Target Upside63.87% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast2752.05%
EPS Growth Forecast87.57%